Connect with us

Economics

Best Penny Stocks to Buy Right Now? Check These 3 Out As January Ends

Here are three penny stocks to watch this month
The post Best Penny Stocks to Buy Right Now? Check These 3 Out As January Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

on

3 Penny Stocks to Watch in the Second Half of January 2022 

With another volatile day of trading penny stocks finished, many investors are looking for the best stocks to buy. Right now, there are several events that are in flux, resulting in massive market movements. 

But, with the right strategy on hand, investors can take advantage of these movements to make money with penny stocks. Of course, the most obvious factor to consider right now is the pandemic and specifically the Omicron Variant. While investors are optimistic about this, it is still a cause for concern. As a side effect of this, we’ve witnessed inflation rates rise, unemployment numbers move, and so on. 

[Read More] 3 Penny Stocks To Watch That Are Climbing During Today’s Session

So, to keep a firm grasp on your portfolio, all of these factors should be used as a part of your strategy. As we move into the rest of 2022, investors should also consider what could happen in that timeline. Having a consistent idea of the short and long-term factors that will impact your portfolio, is always a good idea. With this in mind, let’s take a look at three penny stocks to add to your watchlist as January comes to an end. 

3 Penny Stocks For Your January Watchlist 

  1. Ambev ADR (NYSE: ABEV
  2. Evofem Biosciences Inc. (NASDAQ: EVFM
  3. New Gold Inc. (NYSE: NGD

Ambev ADR (NYSE: ABEV) 

Ambev is a penny stock that we have covered numerous times in the past few months. And while not much news has out about the company in that time, it has made some significant strides in value. If you’re not familiar, Ambev is a Brazilian company that produces and distributed a large range of both alcoholic and non-alcoholic beverages. Its most notable products are its large range of beer brands. 

At the end of last year, Ambev reported its Q3 2021 financial results. In the results, the company posted a YoY growth in profit of more than 57%. In addition, its net revenues pushed up by more than 18%. The majority of these gains are due to increased sales volume in Brazil, Central America, and Southern Latin America. 

What we see is that during both times of economic turmoil and prosperity, sales for alcohol tend to trend upward. While it is hard to say with certainty whether this can continue at the current rate for ABEV, we do know that many are interested in the company. And with these stellar results, ABEV stock could be worth adding to your list of penny stocks to watch. 

Evofem Biosciences Inc. (NASDAQ: EVFM) 

On January 19th, shares of EVFM stock managed to shoot up by over 22%. This is a major gain that brings its one-month uptick to over 30%. While many large gains like this occur without news, Evofem made an exciting announcement during premarket trading today.

[Read More] 4 Penny Stocks To Buy For Under $4 Right Now

It stated that in the fourth quarter of last year, it recorded net sales for Phexxi prescriptions. The company stated that it increased the number of units dispersed by over 80% with a 69% increase in the total prescriptions of the drug. On top of this, the company brought in more than double net product sales, coming out to $3.5 million with a reduced net cash burn. 

“Strong demand for Phexxi and gross-to-net improvement in the fourth quarter enabled us to deliver over $3.5 million in net sales – more than twice Q3 levels, and ahead of the current consensus estimate. More than 55,000 women made the Phexxi choice in 2021 and our refill rate continues to rise, demonstrating high satisfaction amongst Phexxi users.”

The CEO of Evofem, Saundra Pelletier

This is all highly exciting news for the women’s focused biotech penny stock. And with the sales of Phexxi beginning to increase and FDA approved, the company looks like it could be in a great position to keep growing. Whether this makes EVFM stock a worthwhile addition to your penny stocks watchlist or not is up to you. 

Penny_Stocks_to_Watch_Evofem

New Gold Inc. (NYSE: NGD) 

Today, shares of NGD stock managed to shoot up by over 10%, alongside several other gold stocks. Before we get into what New Gold does it’s worth looking into why it climbed today. The main reason behind the uptick in the gold industry comes as the price of gold has pushed up. This comes after yesterday’s major bear market which saw old drop to around $1,807 per ounce. 

On January 19th, gold climbed to over $1,840 by EOD indicating a one-day rise of over 1.5%. If you’re not familiar, New Gold is a Canadian mining company with two assets producing gold in Canada. The company has a large stake in both the Rainy River and New Afton mines as well as a 5% stake in Artemis Gold Inc. Recently, the company announced the release of its fourth quarter financial results as well as its 2022 outlook. 

“2021 was not without its challenges for New Gold, but we continued to execute on our plans, with the fourth quarter representing our strongest quarter of the year, allowing us to meet our updated consolidated gold equivalent production guidance. Rainy River’s fourth quarter production was up 16% compared to the third quarter, representing Rainy River’s strongest quarter over the last two years.”

CEO of New Gold Inc., Renaud Adams

While this gain is major, it is not highly characteristic of the gold industry at large. So, keep the large speculation that is occurring right now in mind before deciding whether NGD stock is right for you. 

Penny_Stocks_to_Watch_New

Which Penny Stocks Are on Your Buy List Right Now?

If you’re looking for the best penny stocks to buy, there are hundreds of options to choose from. While it can be difficult to pick the best ones for your watchlist, using information as a guide is paramount. 

[Read More] Trading Penny Stocks? Top Stock Market News For January 19th, 2022

If you have a proper trading strategy on hand and a commitment to understanding how to trade penny stocks, making money with small caps can be much easier than previously imagined. Considering all of this, do you think that penny stocks are worth buying right now or not?


If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!


The post Best Penny Stocks to Buy Right Now? Check These 3 Out As January Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Economics

“This Is A Crucible Moment” – Sequoia’s Ominous Warning To Companies On How To “Avoid The Death Spiral”

"This Is A Crucible Moment" – Sequoia’s Ominous Warning To Companies On How To "Avoid The Death Spiral"

"This is not a time to panic. It is…

Published

on

"This Is A Crucible Moment" - Sequoia's Ominous Warning To Companies On How To "Avoid The Death Spiral"

"This is not a time to panic. It is a time to pause and reassess," begins the thought-provoking presentation from veteran venture capital firm Sequoia Capital.

But that's about as 'positive' as they get as the founders of the firm warn of a prolonged market downturn and urges the startups in its portfolio to preserve cash and brace for worse to come.

"We believe this is a Crucible Moment, one that will present challenges and opportunities for many of you. First and foremost, we must recognize the changing environment and shift our mindset to respond with intention rather than regret."

And in its somewhat ubiquitous historically grim outlooks (its "R.I.P Good Times" in 2008 and "Black Swan" memo in March 2020 have become legendary) don't expect a quick rescue and recovery this time.

"Sustained inflation, and geopolitical conflicts further limit the ability for a quick-fix policy solution. As such, we do not believe that this is going to be another steep correction followed by an equally swift V-shaped recovery, like we saw at the outset of the pandemic," the note said.

They argue that it will be "Survival of the Quickest"...

In particular, Sequoia urged companies to look at cutting projects, R&D, marketing, and other expenses, noting that companies should be ready to cut in the next 30 days.

"We expect the market downturn to impact consumer behaviour, labour markets, supply chains and more. It will be a longer recovery and while we can't predict how long, we can advise you on ways to prepare and get through to the other side," it said.

The founders/CEOs who face reality, adapt fast, have discipline rather than regret will not just survive, but win, noting that "It is easier to preserve cash when you have more than six months left. Recruiting is about to get easier. All the FANG have hiring freezes."

They conclude their presenttation by noting that:

"At Sequoia, we believe that the one who wins is the one most prepared."

In other words America, brace for capex cuts, hiring freezes to accelerate, and growth to evaporate.

*  *  *

Read the full presentation below:

Tyler Durden Thu, 05/26/2022 - 15:45

Read More

Continue Reading

Economics

Best Day For Discretionary Stocks Since COVID-Crash As Consumer Recession Bets Get Steamrolled

Best Day For Discretionary Stocks Since COVID-Crash As Consumer Recession Bets Get Steamrolled

A week ago, following dismal guidance by Walmart,…

Published

on

Best Day For Discretionary Stocks Since COVID-Crash As Consumer Recession Bets Get Steamrolled

A week ago, following dismal guidance by Walmart, Target indicated that it is seeing a shift in the consumer wallet away from the pandemic purchases and into reopening purchases - including apparel - and the pace of this shift caught some retailers off guard on inventory. WMT, COST, and TGT all saw their stocks fall sharply last week as investor concerns around a US consumer slowdown mounted and investors reconsidered just where, if anywhere, you can play "defense" in the current market.

But as Goldman's Chris Hussey writes today, this week, results from companies like DKS, Macy's, JWN, WSM, DLTR, and DG painted a decidedly different picture.

Deep discount retailers Dollar Tree - or rather Dollar 25 Tree - and Dollar General both posted strong results and DLTR raised top-line guidance.

Which isn't surprising: as we discussed in "Middle Class Is Shutting Down As Spending By The Rich Remains Robust" when consumers are trading down - as they are doing now due to Biden's runaway inflation - dollar stores see more business.

As a result, Dollar Tree surged as much as 20% on Thursday, the biggest intraday move since October 2020. Evercore ISI said Dollar Tree's move to a "$1.25 price point" last November from $1 “came in the nick of time" adding that "given the broad-based inflationary cost pressures, the 25% price increase drove material sales and margin upside for both the namesake division and the total company," wrote analyst Michael Montani who also said that while freight, transport, and labor headwinds are real, some of the pressure cited by Target last week was likely company specific.

The analyst concluded that the read-across from DG and DLTR is “favorable,” and it seems that the low-end consumer is “hanging in better than initially thought.” Or rather, the middle-class is getting crushed and it has no choice but to trade down to the cheapest retail outlets.

And with countless shorts having piled up and getting massively squeezed, the S&P 500 Consumer Discretionary Index today has risen as much as 5.6%, its best day since April 2020, as optimism on the health of the consumer returns following a string of better-than-expected earnings reports from retailers.

Top performers in the S5COND index include Dollar Tree, Dollar General, Norwegian Cruise, Caesars Entertainment and Carnival; the Discretionary Index is on pace for its best week since March 18, when the group climbed 9.3%; the index sank 7.4% as Walmart and Target reports spooked investors. The index is still down almost 30% YTD.

"Retail earnings are bullish.... with four blow-outs,” said Vital Knowledge’s Adam Crisafulli, referring to quarterly reports from Williams-Sonoma, Macy’s, Dollar General, and Dollar Tree.  “The overall retail industry is experiencing stark changes and the market is incorrectly conflating these shifts with underlying demand weakness when the actual health of the consumer is much better than it seems,” Crisafulli says, although there are many - this website included - who wholeheartedly disagree with his optimistic view of the US consumer.

Remarkably, thanks to today’s rally, even Burlington Stores, which sank as much as 12% in premarket on disappointing results, is trading up as much as 11% and some say, the rally helped reverse the earlier tumble in NVDA shares.

The discretionary group is also getting a boost from airline operators Southwest and JetBlue, helping travel-related names, while on the economic front, better-than-expected personal consumption (for the revised Q1 GDP print). and jobless claims may be adding to the bullishness according to Bloomberg.

Tyler Durden Thu, 05/26/2022 - 15:00

Read More

Continue Reading

Spread & Containment

Asymptomatic SARS-CoV-2 infections responsible for spreading of COVID-19 less than symptomatic infections

Based on studies published through July 2021, most SARS-CoV-2 infections were not persistently asymptomatic, and asymptomatic infections were less infectious…

Published

on

Based on studies published through July 2021, most SARS-CoV-2 infections were not persistently asymptomatic, and asymptomatic infections were less infectious than symptomatic infections. These are the conclusions of an update of a systematic review and meta-analysis publishing May 26th in the open access journal PLOS Medicine by Diana Buitrago-Garcia of the University of Bern, Switzerland, and colleagues.

Credit: Monstera, Pexels (CC0, https://creativecommons.org/publicdomain/zero/1.0/)

Based on studies published through July 2021, most SARS-CoV-2 infections were not persistently asymptomatic, and asymptomatic infections were less infectious than symptomatic infections. These are the conclusions of an update of a systematic review and meta-analysis publishing May 26th in the open access journal PLOS Medicine by Diana Buitrago-Garcia of the University of Bern, Switzerland, and colleagues.

Debate about the level and risks of asymptomatic SARS-CoV-2 infections continues, with much ongoing research. Studies that assess people at just one time point can overestimate the proportion of true asymptomatic infections because those who go on to later develop symptoms are incorrectly classified as asymptomatic rather than presymptomatic. However, other studies can underestimate asymptomatic infections with research designs that are more likely to include symptomatic participants.

The new paper was an update of a living (as in, regularly updated) systematic review first published in April 2020, which includes additional, more recent studies through July 2021. 130 studies were included, with data on 28,426 people with SARS-CoV-2 across 42 countries, including 11,923 people defined as having asymptomatic infection. Because of extreme variability between included studies, the meta-analysis did not calculate a single estimate for asymptomatic infection rate, but it did estimate the inter-quartile range to be that 14–50% of infections were asymptomatic. Additionally, the researchers found that the secondary attack rate—a measure of the risk of transmission of SARS-CoV-2 — was about two-thirds lower from people without symptoms than from those with symptoms (risk ratio 0.32, 95%CI 0.16–0.64).

“If both the proportion and transmissibility of asymptomatic infection are relatively low, people with asymptomatic SARS-CoV-2 infection should account for a smaller proportion of overall transmission than presymptomatic individuals,” the authors say, while also pointing out that “when SARS-CoV-2 community transmission levels are high, physical distancing measures and mask-wearing need to be sustained to prevent transmission from close contact with people with asymptomatic and presymptomatic infection.”

Coauthor Nicola Low adds, “The true proportion of asymptomatic SARS-CoV-2 infection is still not known, and it would be misleading to rely on a single number because the 130 studies that we reviewed were so different. People with truly asymptomatic infection are, however, less infectious than those with symptomatic infection.”

#####

In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine:

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003987  

Citation: Buitrago-Garcia D, Ipekci AM, Heron L, Imeri H, Araujo-Chaveron L, Arevalo-Rodriguez I, et al. (2022) Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis. PLoS Med 19(5): e1003987. https://doi.org/10.1371/journal.pmed.1003987

Author Countries: Switzerland, France, Spain, Argentina, United Kingdom, Sweden, United States, Colombia

Funding: This study was funded by the Swiss National Science Foundation http://www.snf.ch/en (NL: 320030_176233); the European Union Horizon 2020 research and innovation programme https://ec.europa.eu/programmes/horizon2020/en (NL: 101003688); the Swiss government excellence scholarship https://www.sbfi.admin.ch/sbfi/en/home/education/scholarships-and-grants/swiss-government-excellence-scholarships.html (DBG: 2019.0774) and the Swiss School of Public Health Global P3HS stipend https://ssphplus.ch/en/ (DBG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


Read More

Continue Reading

Trending